Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
SUMMIT Study: A Study of Persistence to Bonviva (Ibandronate) Once Monthly in Women With Post-Menopausal Osteoporosis.
- Conditions
- Post Menopausal Osteoporosis
- Interventions
- First Posted Date
- 2007-10-17
- Last Posted Date
- 2015-08-18
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 596
- Registration Number
- NCT00545480
A Study of Adherence to Once Monthly Ibandronate (Bonviva) in Women With Post-Menopausal Osteoporosis, Supported by a Patient Relationship Program (PRP)
- First Posted Date
- 2007-10-17
- Last Posted Date
- 2016-10-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 716
- Registration Number
- NCT00545363
A Study to Assess the Efficacy of Rituximab (MabThera) in First Line Treatment of Chronic Lymphocytic Leukemia (CLL)
- Conditions
- Leukemia, Lymphocytic, Chronic, B-Cell
- Interventions
- First Posted Date
- 2007-10-17
- Last Posted Date
- 2019-01-16
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 86
- Registration Number
- NCT00545714
- Locations
- 🇪🇸
Hospital Clinico Universitario Lozano Blesa; Servicio de Hematologia, Zaragoza, Spain
🇪🇸Hospital Clinico Universitario de Salamanca;Servicio de Hematologia, Salamanca, Spain
🇪🇸Hospital Universitario Puerta del Mar; Servicio de Hematologia, Cádiz, Cadiz, Spain
A Study of Oseltamivir (Tamiflu) for Treatment of Influenza in Immunocompromised Participants.
- First Posted Date
- 2007-10-17
- Last Posted Date
- 2018-07-12
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 228
- Registration Number
- NCT00545532
- Locations
- 🇺🇸
Baylor University Medical Center Transplant Administration, Dallas, Texas, United States
🇺🇸Sammons Cancer Center-Baylor University; Blood & Marrow Transplantation, Dallas, Texas, United States
🇺🇸UCLA Medical center Medicine/Nephrology, Los Angeles, California, United States
A Study of Bonviva (Ibandronate) Once Monthly in Post-Menopausal Women With Osteopenia.
- Conditions
- Post-Menopausal Osteopenia
- Interventions
- Drug: Placebo
- First Posted Date
- 2007-10-17
- Last Posted Date
- 2017-01-26
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 150
- Registration Number
- NCT00545207
A Study of Once Monthly Bonviva (Ibandronate) in Prevention of Glucocorticoid-Induced Osteoporosis.
- First Posted Date
- 2007-10-17
- Last Posted Date
- 2016-05-12
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 140
- Registration Number
- NCT00545051
BONCURE Study: A Study of Monthly Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis on Bisphosphonate Therapy.
- First Posted Date
- 2007-10-17
- Last Posted Date
- 2016-10-28
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 677
- Registration Number
- NCT00545779
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus COPEGUS (Ribavirin) With or Without Pioglitazone in Treatment-Naive Patients With Chronic Hepatitis C and Insulin Resistance.
- Conditions
- Hepatitis C, Chronic
- Interventions
- First Posted Date
- 2007-10-17
- Last Posted Date
- 2012-05-07
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 155
- Registration Number
- NCT00545233
BEATRIS Study: A Study of Adherence to Bonviva (Ibandronate) Once Monthly in Women With Post-Menopausal Osteoporosis
- Conditions
- Postmenopausal Osteoporosis
- Interventions
- First Posted Date
- 2007-10-17
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 585
- Registration Number
- NCT00545909
A Study of CellCept (Mycophenolate Mofetil) in Combination Therapy in Liver Transplant Patients.
- Conditions
- Liver Transplantation
- Interventions
- Drug: Corticosteroids, IVDrug: Corticosteroids, PO
- First Posted Date
- 2007-10-17
- Last Posted Date
- 2014-07-14
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 180
- Registration Number
- NCT00545402